
Jan 8 (Reuters) - MoonLake Immunotherapeutics MLTX.O:
MOONLAKE IMMUNOTHERAPEUTICS ANNOUNCES POSITIVE OUTCOME FROM TYPE B MEETING WITH U.S. FDA AND ANNOUNCES INVESTOR DAY
MOONLAKE IMMUNOTHERAPEUTICS - FDA CONFIRMS MOONLAKE CAN ESTABLISH SEE WITHOUT ADDITIONAL TRIALS
MOONLAKE IMMUNOTHERAPEUTICS - PLANS BLA SUBMISSION FOR SLK IN HS IN H2 2026